Pay in 4 interest-free payments of $5.83 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
The GLP1RAs, dulaglutide, exenatide, semaglutide, liraglutide, tirzepatide, and lixisenatide are FDAapproved for use in the treatment of obesity and type 2 diabetes mellitus (DM), particularly to reduce cardiovascular risk and improve glycemic control.1,2,3 GLP1RAs work by mimicking glucagon-like peptide-1 (GLP-1), an incretin, that functions to subdue appetite, delay gastric emptying, and regulate homeostasis of glucose
PMID: 25908079, PMCID: PMC5459371, DOI: 10.1016/j.jacc.2014.12.071
Can induce spontaneous erections as a side effect
doi:10.1054/ghir.1999.9998 Greenwood-Van Meerveld B, Tyler K, Mohammadi E, Pietra C
US$ 23.33
US$ 26.95
US$ 28.58
